ASCO GU 2024

Is "more" always better?

BRCAAway - practice changing or hypothesis generating data?

Combination vs. monotherapy - a great new option for high-risk patients

Cabo + IO: Interesting but not practice changing?!

Further testing before olaparib combination

Relugolix combined with androgen signaling in real word experience

Localized PCa - news for radiotherapy and biochemical recurrence

Quality of life under intensive therapy

BRCAaway - PARP combination study

Salvage radiation with anti-androgen superior to radiation alone

Long-term dose escalation - Therapy in high-risk prostate cancers

Evaluating the recombination-repair mutations in patients with mCRPC

Combination NHT + PARP makes sense

Therapy Intensification Still Neglected in mHSPC

Enzalutamide therapy as option for biochemical recurrence

Olaparib + Arbiraterone better compared to either alone

Insights and news for mCRPC

Gleason 3+3 - cancer or not?

Higher radiation is effective in high-risk PCA

What about the clinical benefit?

Combination of cabozantinib & checkpoint inhibitor

Cognitive function in ART treatment

First positive study of IO therapy in mCRPC

Dose de-escalation in different ways

Stockholm3 validated in multiethnic cohort

Still a difficult time for androgenic inhibitors in mCRPC

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi)

Orta riskli PCa da RARP sirasinda LND dan vazgecilebilir mi?

Post-RP salvage radyoterapi hormonoterapi ile konbine edilmeli

Kognitiv påverkan av abirateron och enzalutamid?

SEPTA calismasi: Stockholm3 un multietnik hasta grubunda validasyonu

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO GU '24

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

Kombination av cabozantinib och immunterapi

Une période encore difficile pour les inhibiteurs androgéniques dans le cancer de la prostate métastatique résistant à la castration.

Gleason 3+3 ska vi kalla de cancer eller inte?

BRCAAway - PARP hämmare, abiraterone eller i kombination

The emerging field of biomarkers in bladder cancer

ADC + ICI: new data for platinum-refractory bladder cancaer patients

New standard of care, but still open questions!

Advances in (neo)-adjuvant treatment in urothelial cancer

Adjuvant Nivolumab Shows Promise in Boosting Long-Term Survivorship for High-Risk Muscle-Invasive Urothelial Carcinoma

Adjuvant therapy in urothelial carcinoma : is the equation resolved?

ASCO GU24 - Highlights in Bladder cancer

Pembrolizumab adjuvant in bladder cancer

EV + Pembro new first-line standard in localized metastatic bladder cancer

Highlights in bladder cancer at ASCO GU24

Perioperative adjuvant therapy in urothelial cancer

Update M1 urothelial cancer

EV as standard in 3rd line mUC

Biomarker update

MIBC: adjuvant PD1 - all set?!

Should we start forgetting the Galsky Criteria in advanced urothelial carcinoma?

HER2 and bladder cancer

Update on EV-302

Another success for an ICI?

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

¿Deberíamos empezar a olvidarnos de los Criterios de Galsky en cancer urotelial avanzado?

Tratamiento adyuvante en cancer urotelial: ¿está resuelta la ecuación?

Encore un succès pour une ICI ?

Terapia adyuvante perioperatoria en el cáncer de vejiga

Novedades sobre EV-302

Adjuvant therapy in kidney cancer: Is immunotherapy the answer?

Trial updates at ASCO GU24: Are the follow-up data confirmatory?

Subcutaneous vs. intravenous application: ready for everyday clinics?

No surprise with the QoL data

Perioperative treatment in renal cell carcinoma - did we close the circle?

Highlights in kidney cancer at ASCO GU24

Tumorburden and outcome

Overall survival benefit - Pembro after surgery

Practice changing adjuvant therapy?!

Long-term outcome

ASCO GU24 - Highlights in renal cell carcinoma

Long-term follow-up of first-line trials

Better QoL with Belzutifan

Cabozantinib Plus Atezolizumab in Adrenocortical Carcinoma Falls Short of Expectations, Emphasizing Ongoing Need for Treatment Innovations

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark CheckMate-9ER Trial: Prolonged Efficacy and Safety Reinforce Standard of Care in Advanced Renal Cell Carcinoma

Belzutifan: Updates on QoL

Durable effects of Ipi-Nivo

Subcutaneous Nivolumab Matches IV Formulation in Clear Cell Renal Cell Carcinoma, Paving the Way for Enhanced Therapy Delivery and Safety

Long-Term Data on NIVO+IPI in aRCC

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Tratamiento perioperatorio en cancer renal: ¿Hemos cerrado el círculo?